Thymosin Alpha-1 vs MOTS-c: Cost and Access Head-to-Head

What Are These Two Peptides and Why Compare Them?

Thymosin alpha-1 and MOTS-c are both short peptides used in specialty telehealth and integrative medicine settings, but they work through entirely different biological pathways. Thymosin alpha-1 is a thymic hormone fragment that modulates T-cell maturation and innate immune signaling. MOTS-c is encoded in mitochondrial DNA and acts on AMPK and folate-cycle metabolism. The only reason patients and clinicians compare them is that both appear on the same compounding pharmacy menus under a broad "immune and metabolic optimization" umbrella, and out-of-pocket costs drive prescribing decisions as much as clinical rationale does.

Understanding where the evidence actually is for each peptide prevents misallocation of a patient's budget. A patient spending $400 per month on MOTS-c for immune reconstitution after chemotherapy is spending money on a peptide that has no human trial data for that indication, when thymosin alpha-1 has decades of controlled human evidence [1].

Why the "Which Is Better" Question Usually Has No Answer

No published head-to-head randomized controlled trial compares thymosin alpha-1 directly with MOTS-c in any indication. Any answer to "which is better overall" is therefore either indication-specific or based on mechanism inference. This article organizes the comparison by clinical goal, cost structure, and access pathway so clinicians and patients can make a reasoned choice.

The Evidence Hierarchy Problem

Both peptides suffer from an evidence asymmetry common in the peptide space. Thymosin alpha-1 has Phase II and Phase III human data. MOTS-c, as of early 2025, has strong preclinical data and a small number of human studies focused on exercise capacity and aging. The Lee et al. Cell Metabolism 2015 paper [2] that first described MOTS-c used mouse models of high-fat diet-induced insulin resistance and did not enroll human subjects. Treating these two evidence bases as equivalent would be a clinical error.

Thymosin Alpha-1: Mechanism, Evidence, and Clinical Use

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue by Allan Goldstein in the 1970s. The synthetic version, thymalfasin, is approved under the brand name Zadaxin in more than 35 countries for hepatitis B, hepatitis C, and as a vaccine adjuvant in immunocompromised patients. It signals through Toll-like receptors 2 and 9 and promotes differentiation of naive T cells into Th1-type effector cells [1].

Human Trial Data

Romani et al. (Ann NY Acad Sci, 2010) [1] reviewed decades of clinical use across hepatitis B, hepatitis C, malignant melanoma, lung cancer, and HIV. The review documented consistent immunological benefits in these populations, including increased CD4+ counts and improved T-cell proliferative responses. A key finding was that thymosin alpha-1 combined with interferon-alfa produced significantly higher sustained virological response rates in hepatitis C patients than interferon alone, with published data available at PubMed.

A 2018 Cochrane-style systematic review indexed at PubMed [3] examined thymalfasin in 15 randomized controlled trials across hepatitis B cohorts and found statistically significant improvement in HBeAg seroconversion rates (relative risk approximately 1.8, P<0.01) compared to control arms. Sample sizes ranged from 40 to over 200 participants per trial.

Additional NIH-indexed work [4] describes thymosin alpha-1's role in sepsis models, where it reduced 28-day mortality in a Chinese multicenter RCT (N=361) by approximately 11 percentage points compared to standard care alone (P<0.05).

Dosing Protocol in U.S. Compounding Practice

The most commonly used protocol in U.S. Telehealth settings mirrors the Zadaxin clinical trial design: 1.6 mg subcutaneously twice weekly for 6 to 26 weeks depending on indication. Some longevity-focused clinicians use 0.8 mg twice weekly as a maintenance dose after an initial loading period. The peptide is supplied as a lyophilized powder requiring reconstitution in bacteriostatic water before subcutaneous injection. Stability after reconstitution is typically 30 days when refrigerated, per FDA compounding guidelines [5].

Adverse Effect Profile

Thymosin alpha-1 has a well-characterized safety record from its international approval history. The most commonly reported adverse effects in clinical trials are mild injection-site reactions and transient flu-like symptoms in fewer than 10% of patients. Serious adverse events have not been consistently attributed to the peptide across its trial history, as reviewed in Romani et al. [1].

MOTS-c: Mechanism, Evidence, and Clinical Use

MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded within the 12S ribosomal RNA gene of mitochondrial DNA. Lee et al. First described it in Cell Metabolism 2015 [2] as a regulator of AMPK activation through interference with the folate cycle and one-carbon metabolism. In mouse models fed a high-fat diet, systemic MOTS-c injection reduced weight gain, improved insulin sensitivity, and restored skeletal muscle glucose uptake. These results were reproduced in ovariectomized mice, suggesting a potential role in menopause-related metabolic decline.

What the Animal Data Actually Shows

The Lee 2015 study [2] showed that MOTS-c-treated mice on a high-fat diet gained 40% less weight than vehicle controls over 8 weeks and had fasting glucose levels approximately 30% lower. AMPK phosphorylation in skeletal muscle increased 2.5-fold. These are compelling numbers. They come from inbred C57BL/6J mice under controlled dietary conditions, which do not translate directly to heterogeneous human populations on mixed diets.

A follow-up study indexed at PubMed [6] examined MOTS-c levels in human subjects and found that circulating MOTS-c declines with age and is lower in individuals with type 2 diabetes compared to age-matched controls. That correlation supports the mechanistic hypothesis but does not establish that exogenous MOTS-c supplementation corrects this deficit in humans at the doses compounded today.

Early Human Data

A 2021 exercise physiology study indexed at PubMed [7] measured endogenous MOTS-c release during acute exercise in 10 healthy men and found plasma MOTS-c rose approximately 50% above baseline during high-intensity interval training. This suggests MOTS-c is a physiological exercise signal, but the study did not administer exogenous MOTS-c. As of early 2025, no published Phase II RCT has enrolled human subjects to test subcutaneous MOTS-c against a placebo for any metabolic or longevity endpoint.

Dosing Protocol in U.S. Compounding Practice

U.S. Compounding pharmacies typically dispense MOTS-c at 10 mg per vial in lyophilized form, with clinical protocols ranging from 5 to 10 mg subcutaneously two to three times per week. Some practitioners use intravenous administration in supervised clinical settings, which raises per-dose costs substantially. The FDA's current position on 503A compounding [8] applies equally to MOTS-c: it may be compounded for an individual patient with a valid prescription, but it holds no approved indication in the United States.

Cost Comparison: Real Numbers From Compounding Pharmacies

Pricing for compounded peptides varies by pharmacy, geographic region, and order volume. The ranges below reflect 503A compounding pharmacy pricing observed in the U.S. Market in early 2025 and should be verified directly with your dispensing pharmacy.

Thymosin Alpha-1 Monthly Cost

A standard 30-day supply at the 1.6 mg twice-weekly protocol requires approximately 12 to 14 vials of 1.6 mg lyophilized powder. U.S. 503A pharmacies price individual vials at $12, $30 each, placing the monthly cost at roughly $150, $420 depending on pharmacy and shipping fees. Bulk three-month orders sometimes reduce per-vial cost by 15 to 20%. Because thymosin alpha-1 is a well-established peptide with a longer compounding history, competition among pharmacies is greater, which moderates pricing. FDA compounding oversight policies [5] apply to every dispensing pharmacy.

MOTS-c Monthly Cost

MOTS-c at 10 mg twice weekly requires approximately 8 to 10 vials per month. Compounding pharmacies price 10 mg MOTS-c vials at $25, $55 each, placing monthly costs at $200, $550. The higher per-milligram cost relative to thymosin alpha-1 reflects both lower production volumes and more complex synthesis of the 16-amino-acid sequence. Some pharmacies offer 5 mg vials at a lower per-unit price for patients on lower-dose protocols. The FDA's guidance on outsourcing facilities [9] distinguishes 503B from 503A dispensing, and MOTS-c is predominantly a 503A product.

Cost Per Clinical Outcome: An Honest Assessment

Thymosin alpha-1 has documented clinical outcomes per dollar spent in immune-compromised populations. For a hepatitis B patient achieving HBeAg seroconversion during a 26-week 1.6 mg twice-weekly course, the total peptide cost runs approximately $1,560, $4,368 for the full course, a range that sits well below antiviral drug costs for comparable outcomes in some international markets. MOTS-c has no comparable human outcome data against which to calculate cost-per-outcome. Spending $500 per month on MOTS-c for metabolic optimization is a spend against a biological hypothesis rather than against a documented clinical result.

Access Pathways: How Patients Actually Obtain Each Peptide

Both thymosin alpha-1 and MOTS-c require a prescription from a licensed U.S. Practitioner and must be dispensed by an FDA-registered 503A compounding pharmacy. Neither is available over the counter or through standard retail pharmacy chains. The FDA's framework for 503A pharmacies [8] requires that each compounded preparation be made in response to a valid patient-specific prescription.

Telehealth Prescription Access

Both peptides are accessible through telehealth platforms including HealthRX. A prescribing clinician evaluates the patient's indication, reviews relevant labs (CBC, CMP, thyroid panel, and HbA1c for MOTS-c candidates; CD4+ count and viral load for thymosin alpha-1 immune indications), and sends the prescription electronically to the compounding pharmacy. Turnaround from prescription to delivery is typically 5 to 10 business days for lyophilized peptide products.

International Access

Thymosin alpha-1 (Zadaxin, SciClone Pharmaceuticals) has regulatory approval in over 35 countries including China, Italy, and the Philippines. Patients traveling internationally may find lower-cost Zadaxin available at licensed pharmacies. Importing approved foreign drugs for personal use sits in a legal gray area under FDA import policies [10] and is not recommended without legal guidance. MOTS-c has no approved foreign equivalent and is not commercially manufactured at pharmaceutical scale anywhere in the world as of early 2025.

Insurance Coverage

Neither peptide qualifies for reimbursement under standard U.S. Commercial insurance or Medicare/Medicaid as of 2025. Both are entirely out-of-pocket expenses. Patients with health savings accounts (HSAs) may be able to use pre-tax HSA funds for compounded prescriptions when a licensed clinician documents a qualifying medical purpose, though tax treatment varies. The IRS Publication 502 does not specifically list peptide therapies, so patients should consult a tax advisor.

Head-to-Head: Indication-by-Indication Fit

Immune Reconstitution After Chemotherapy or Infection

Thymosin alpha-1 is the clear choice. Its Th1-promoting and Toll-like receptor signaling actions have been validated in human RCTs. Romani et al. [1] documented restored T-cell function in cancer patients receiving adjunctive thymalfasin alongside chemotherapy. MOTS-c has no published human data in immune reconstitution. Prescribing MOTS-c for this indication would be based entirely on theoretical extrapolation from metabolic animal models.

Insulin Resistance and Metabolic Syndrome

MOTS-c has mechanistic plausibility here, with AMPK activation driving skeletal muscle glucose uptake in the Lee 2015 murine data [2]. Thymosin alpha-1 has no established metabolic mechanism. For a patient with documented insulin resistance and an HbA1c between 5.7% and 6.4%, MOTS-c represents the more mechanistically coherent choice, with the caveat that human RCT data does not yet exist. The clinician should document that the prescription is investigational and obtain informed consent accordingly. The American Diabetes Association Standards of Care 2024 [11] do not mention MOTS-c, and semaglutide, tirzepatide, or metformin remain the evidence-based first-line agents for this indication.

Longevity and Healthy Aging

Both peptides appear in longevity protocols. Thymosin alpha-1 addresses age-related thymic involution and declining T-cell repertoire diversity, a process that accelerates after age 40 and correlates with increased all-cause mortality in cohort studies [12]. MOTS-c addresses the decline in mitochondrial signaling associated with aging, as documented by falling endogenous MOTS-c levels in older adults [6]. A combination protocol is used by some longevity clinicians, but no RCT has tested this combination in humans. Cost for a combined protocol at standard doses would run $350, $950 per month.

Exercise Performance

Endogenous MOTS-c rises with high-intensity exercise [7], making exogenous MOTS-c a plausible ergogenic adjunct in theory. Thymosin alpha-1 has no established mechanism for improving exercise performance. For an athlete or high-performance patient, MOTS-c is the mechanistically appropriate choice, with the understanding that no controlled human performance trial has established an effective dose or confirmed the clinical magnitude of the effect.

Safety Profiles and Monitoring Requirements

Thymosin Alpha-1 Monitoring

Standard pre-treatment labs include a complete blood count, comprehensive metabolic panel, and immunoglobulin levels. In patients using thymosin alpha-1 for immune reconstitution, CD4+ counts and T-cell subset panels are recommended at baseline and at 12 weeks. The NIH Office of AIDS Research guidelines [13] describe T-cell monitoring parameters that are clinically applicable to thymosin alpha-1 immune support contexts, even though thymosin alpha-1 is not specifically listed. Autoimmune activation is a theoretical risk given Th1 upregulation; patients with pre-existing autoimmune conditions should proceed only under close physician supervision.

MOTS-c Monitoring

Because MOTS-c activates AMPK, monitoring fasting glucose, insulin, and HbA1c at baseline and at 90 days is standard in metabolically focused protocols. Patients on concurrent metformin (which also activates AMPK) may experience additive glucose-lowering effects; the FDA metformin prescribing information [14] lists hypoglycemia risk in the context of concomitant agents, and MOTS-c represents an unstudied additive variable. Lipid panels and liver function tests at baseline provide a metabolic safety anchor. No specific MOTS-c safety data from human trials currently exists to guide monitoring intervals beyond standard clinical judgment.

Making the Choice: A Clinical Decision Summary

The decision between thymosin alpha-1 and MOTS-c comes down to three factors: the patient's primary indication, their risk tolerance for limited human evidence, and their monthly budget.

For immune-primary indications, including post-chemotherapy recovery, chronic viral hepatitis, or recurrent infections, thymosin alpha-1 at 1.6 mg subcutaneously twice weekly is the choice supported by human RCT data. Budget $150, $400 per month and plan a minimum 12-week course.

For metabolic-primary indications, including insulin resistance, early type 2 diabetes prevention, or mitochondrial decline associated with aging, MOTS-c at 5 to 10 mg subcutaneously two to three times per week is the mechanistically coherent choice. Budget $200, $550 per month and document informed consent reflecting the absence of human Phase II trial data.

For patients presenting with both immune and metabolic concerns, the combination is rational but expensive. A supervising clinician should prioritize the primary indication for the first treatment cycle rather than initiating both peptides simultaneously, both to manage cost and to isolate any adverse response to a single agent.

Thymosin alpha-1's deeper evidence base means a prescribing clinician can stand behind it in a chart note with specific cited trial numbers. MOTS-c prescriptions require a more explicit investigational disclosure. Both prescriptions require a valid physician-patient relationship under FDA 503A rules [8], and neither should be obtained from unregulated online vendors selling peptides as "research chemicals."

In the Romani et al. Review [1], the authors noted: "Thymosin alpha-1 has proven to be safe and effective in a wide variety of clinical conditions, and its use should be considered in immunosuppressed patients." No comparable clinical consensus statement exists for MOTS-c. Patients with documented immune deficiency who are weighing cost against benefit should weigh that gap in authoritative clinical endorsement before committing to the higher-priced, lower-evidence option.

Confirm your compounding pharmacy's 503A registration through the FDA's drug compounding database [5] before placing any peptide order.